168 related articles for article (PubMed ID: 32077238)
1. Pulsed echinocandin therapy in azole intolerant or multiresistant chronic pulmonary aspergillosis: A retrospective review at a UK tertiary centre.
Osborne W; Fernandes M; Brooks S; Grist E; Sayer C; Hansell DM; Wilson R; Shah A; Loebinger MR
Clin Respir J; 2020 Jun; 14(6):571-577. PubMed ID: 32077238
[TBL] [Abstract][Full Text] [Related]
2. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance.
Takeda K; Suzuki J; Watanabe A; Arai T; Koiwa T; Shinfuku K; Narumoto O; Kawashima M; Fukami T; Tamura A; Nagai H; Matsui H; Kamei K
Med Mycol; 2021 Apr; 59(4):327-334. PubMed ID: 32642756
[TBL] [Abstract][Full Text] [Related]
3. Emergence of azole resistant-
Danion F; Duréault A; Gautier C; Senechal A; Persat F; Bougnoux ME; Givel C; Couderc LJ; Lortholary O; Garcia-Hermoso D; Lanternier F
J Med Microbiol; 2020 Jun; 69(6):844-849. PubMed ID: 32459615
[No Abstract] [Full Text] [Related]
4. Positive Aspergillus PCR as a marker of azole resistance or sub-therapeutic antifungal therapy in patients with chronic pulmonary aspergillosis.
Moazam S; Eades CP; Muldoon EG; Moore CB; Richardson MD; Rautemaa-Richardson R
Mycoses; 2020 Apr; 63(4):376-381. PubMed ID: 31981256
[TBL] [Abstract][Full Text] [Related]
5. Management of chronic pulmonary aspergillosis.
Izumikawa K; Tashiro M; Kohno S
Ann N Y Acad Sci; 2012 Dec; 1272():40-8. PubMed ID: 23231713
[TBL] [Abstract][Full Text] [Related]
6. Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis.
Keir GJ; Garfield B; Hansell DM; Loebinger MR; Wilson R; Renzoni EA; Wells AU; Maher TM
Thorax; 2014 Mar; 69(3):287-8. PubMed ID: 24029745
[TBL] [Abstract][Full Text] [Related]
7. Emergence of Echinocandin Resistance Due to a Point Mutation in the
Jiménez-Ortigosa C; Moore C; Denning DW; Perlin DS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923871
[TBL] [Abstract][Full Text] [Related]
8. Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?
Hamprecht A; Morio F; Bader O; Le Pape P; Steinmann J; Dannaoui E
Mycopathologia; 2018 Feb; 183(1):151-160. PubMed ID: 28653258
[TBL] [Abstract][Full Text] [Related]
9. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.
Verweij PE; Ananda-Rajah M; Andes D; Arendrup MC; Brüggemann RJ; Chowdhary A; Cornely OA; Denning DW; Groll AH; Izumikawa K; Kullberg BJ; Lagrou K; Maertens J; Meis JF; Newton P; Page I; Seyedmousavi S; Sheppard DC; Viscoli C; Warris A; Donnelly JP
Drug Resist Updat; 2015; 21-22():30-40. PubMed ID: 26282594
[TBL] [Abstract][Full Text] [Related]
10. Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus.
Wiederhold NP; Najvar LK; Jaramillo R; Olivo M; Wickes BL; Catano G; Patterson TF
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405851
[TBL] [Abstract][Full Text] [Related]
11. [Azole-resistant invasive aspergillosis].
van der Linden JW; Warris A; van der Meer JW; Bresters D; Melchers WJ; Verweij PE
Ned Tijdschr Geneeskd; 2009; 153():A765. PubMed ID: 20051169
[TBL] [Abstract][Full Text] [Related]
12. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.
Bongomin F; Harris C; Hayes G; Kosmidis C; Denning DW
PLoS One; 2018; 13(4):e0193732. PubMed ID: 29634721
[TBL] [Abstract][Full Text] [Related]
14. Chronic Pulmonary Aspergillosis: Clinical Presentation and Management.
Evans TJ; Lawal A; Kosmidis C; Denning DW
Semin Respir Crit Care Med; 2024 Feb; 45(1):88-101. PubMed ID: 38154471
[TBL] [Abstract][Full Text] [Related]
15. The emergence of azole resistance in Aspergillus fumigatus complex in New Zealand.
McKinney WP; Vesty A; Sood J; Bhally H; Morris AJ
N Z Med J; 2021 Jun; 134(1536):41-51. PubMed ID: 34140712
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
Olson JA; George A; Constable D; Smith P; Proffitt RT; Adler-Moore JP
Antimicrob Agents Chemother; 2010 Sep; 54(9):3884-94. PubMed ID: 20606065
[TBL] [Abstract][Full Text] [Related]
18. Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta-analysis.
Bongomin F; Asio LG; Olum R; Denning DW
Mycoses; 2020 Sep; 63(9):921-927. PubMed ID: 32542771
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains.
Lamoth F; Juvvadi PR; Gehrke C; Steinbach WJ
Antimicrob Agents Chemother; 2013 Feb; 57(2):1035-9. PubMed ID: 23165466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
